TX HB 1680
deadRelating to prior authorization for prescription drug benefits related to the prevention of human immunodeficiency virus infections.
Texas · 89th Legislature (2025 Regular Session) · lower
- Introduced
- 2025-03-12
- Status date
- —
- Latest action
- 2025-05-12 — Committee report sent to Calendars
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Jones, Ventonprimary
Committees
Not provided by source.
Action timeline
2024-12-19
Filed
filing
2025-03-12
Read first time
introduction,reading-1
2025-03-12
Referred to Insurance
referral-committee
2025-05-07
Considered in public hearing
2025-05-07
Testimony taken/registration(s) recorded in committee
2025-05-07
Left pending in committee
2025-05-07
Considered in formal meeting
2025-05-07
Failed to receive affirmative vote in comm.
committee-failure
2025-05-09
Considered in formal meeting
2025-05-09
Reported favorably w/o amendment(s)
committee-passage,committee-passage-favorable
2025-05-12
Comte report filed with Committee Coordinator
filing
2025-05-12
Committee report distributed
2025-05-12
Committee report sent to Calendars
Versions
Documents
- application/pdf(no extracted text yet)
- text/html(no extracted text yet)
- application/pdf(no extracted text yet)
- text/html(no extracted text yet)
- text/html(no extracted text yet)
- text/html(no extracted text yet)
- text/html(no extracted text yet)
Votes
Not provided by source.
Related bills
- Companion bill: SB 1274
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:33:51.767464Z
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=TX&identifier=HB 1680. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
- Some documents have no extracted text yet, so version comparison may be limited.
See the methodology page for data sources and limitations.